Clinical Trials Logo

Clinical Trial Summary

The investigators will be using nocturnal normobaric hyperoxia therapy in patients with diagnoses of conditions related to retinal ischemia.


Clinical Trial Description

Patients who receive a diagnosis of a condition relate to retinal ischemia and who pass the eligibility criteria will receive an oxygen concentrator to use at home. They will report back in follow up monthly for three to six months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03730779
Study type Interventional
Source Beth Israel Deaconess Medical Center
Contact
Status Withdrawn
Phase Phase 4
Start date November 30, 2018
Completion date January 1, 2020

See also
  Status Clinical Trial Phase
Completed NCT03906383 - Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning in Patients With Type 1 Diabetes N/A
Active, not recruiting NCT03422965 - Perifoveal Vascular Network Assessed by OCT-Angiography in Type I Diabetes Mellitus N/A
Recruiting NCT03061526 - Spectral-domain Optical Coherence Tomography Findings in Retinal Vessel Occlusion
Completed NCT00841373 - Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease Phase 1/Phase 2
Recruiting NCT04038125 - Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME Phase 4
Recruiting NCT06431711 - Fundus Optical coheRence Tomography Angiography Evaluation for Small-vessel Health in Cerebral Small Vessel Disease